The biotech raised $310 million in a Series C financing, taking its valuation to $1.2 billion as it expands its small‑molecule pipeline in endocrinology and immunology.
Omaas Therapeutics announced a $310 million Series C round, boosting its valuation to $1.2 billion and fueling the expansion of its small‑molecule pipeline targeting endocrine and immunology disorders.
Funding round details
The financing was led by a consortium of venture capital firms, with participation from existing investors. The capital will support pre‑clinical and early‑stage clinical programs focused on hormone‑related diseases and immune‑modulating therapies.
Strategic focus on small‑molecule drugs
Omaas aims to differentiate itself by developing orally bioavailable small molecules that can modulate complex pathways traditionally addressed by biologics. This approach promises lower manufacturing costs and greater patient convenience.
Pipeline highlights
- A novel glucagon‑like peptide‑1 (GLP‑1) antagonist for type 2 diabetes management.
- An oral checkpoint inhibitor targeting PD‑1/PD‑L1 interactions for oncology indications.
- A selective estrogen receptor modulator (SERM) under investigation for menopausal symptom relief.
While the company has not disclosed specific timelines, it expects to advance at least two candidates into Phase 1 trials within the next 12 months.
For broader context on the biotech financing landscape, see Business coverage on uxc.news and the company’s profile on Omaas on Momentum.